Method for renal disease diagnosis using Rab23 as marker
AssigneeNational Defense Medical Center
InventorsAnn Chen, Hao-Ai Shui, Shuk-Man Ka
Life of this patent
Estimating the term…
Abstract
Use of Annexin A1 or Rab23 as a biomarker for diagnosing kidney disease or assessing efficacy of kidney disease treatment.
Claims3
A method for diagnosing a renal disorder in a kidney of a subject suspected of having kidney sclerosis, kidney fibrosis, glomerular injury, kidney failure, glomerulosclerosis, focal segmental glomerulosclerosis or glomerulonephritis, comprising providing a kidney tissue sample obtained from the subject, detecting the level of a biomarker in the kidney tissue sample, and determining whether the subject has one of the said disorders based on the level of the biomarker thus detected;
- wherein the biomarker is Rab23 and an elevated level of the biomarker in the subject suspected of having the renal disorder higher than in a healthy subject indicates that the subject has the said renal disorder.
Dependencies are inferred from the claim text.